Latest News Story Headlines
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
2024 Fall Newsletter
Be sure to catch up on the latest happenings in our fall newsletter.
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug.
Calendar & Upcoming Events
Webinar: Grace vs. Forgiveness
Webinar Session, Wednesday, Dec. 4th, 2024 at 6 PM (ET)
Sign Up for the Latest Updates
Get news from Amyloidosis Foundation
in your inbox
By submitting this form, you are consenting to receive marketing emails from : Amyloidosis Foundation, 7151 N. Main St., Suite 2, Clarkston, MI, 48346, US, https://www.amyloidosis.org. You can revoke your consent to receive emails at any time by using SafeUnsubscribe© link, found at the bottom of every email. Emails are serviced by Constant Contract.